New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

The following is a summary of “An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma,” published in the January 2025 issue of Oncology by Pham et al. Over the past ...

The following is a summary of “Skin cancer risk in over 200.000 patients with haematologic malignancies in 30 years; a ...

Cutaneous changes may indicate the presence of or herald the incipient development of internal malignancies. The authors review 24 cutaneous signs, symptoms, diseases, and syndromes associated ...

Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025Series B Financing Funds ...

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell ...

Utilizing an automated, high-throughput platform to generate comprehensive clinical & molecular datasets to enable a real-world evidence approach for improving care of patients with gastrointestinal ...

GT Biopharma (GTBP) announced that the first patient was dosed in a Phase 1 trial evaluating GTB-3650, its second-generation TriKE, for the ...